Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum

Next Previous
Trial Profile

GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Nilotinib (Primary)
  • Indications Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma
  • Focus Therapeutic Use
  • Acronyms GEIS-27

Most Recent Events

  • 23 Jul 2018 From January 2012 to April 2013, 13 patients were assessed for eligibility to the phase I portion of the trial. The clinical cut-off date for the final analyses of the phase II part (in this portion only retroperitoneal liposarcomas or leiomyosarcomas were enrolled ) will be in October 2018, according to results published in the Clinical Cancer Research.
  • 23 Jul 2018 Results (n=13) of phase 1 part published in the Clinical Cancer Research.
  • 14 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top